THOMAS STROSS: Open Payments
NPI 1811391063 · ZEPHYRHILLS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,809 in 91 payments from 13 companies in 2025. Trend: 2023 $1,503 · 2024 $847 · 2025 $1,809
Food & beverage: $1,809
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $401 |
| Alkermes, Inc. | 9 | $273 |
| Otsuka America Pharmaceutical, Inc. | 21 | $222 |
| Teva Pharmaceuticals USA, Inc. | 15 | $195 |
| E.R. Squibb & Sons, L.L.C. | 6 | $188 |
| Novo Nordisk Inc | 1 | $115 |
| ABBVIE INC. | 4 | $99 |
| Vanda Pharmaceuticals Inc. | 3 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| Lundbeck LLC | 3 | $71 |
Products named: INGREZZA, REXULTI, LYBALVI, COBENFY, Ozempic, AUSTEDO XR, VRAYLAR, UZEDY.
Industry payments across FL — which companies pay providers there.
